wp:paragraph --> In a new study presented at the American Psychiatric Association annual meeting, researchers say that people using the test, called GeneSight, are 50% more likely to achieve ...

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

A significant reason for the Hold rating is the recent decision by UnitedHealthcare (UNH) to alter its coverage of GeneSight ... molecular diagnostic test. It operates through the Diagnostics ...

However, a significant challenge emerged when UnitedHealthcare decided to discontinue coverage for multi-gene panel pharmacogenetic testing, including Myriad’s GeneSight test, from January 2025 ...

The insurer plans to restrict coverage for multi-gene panel pharmacogenetic tests, including Myriad's GeneSight, under its commercial and individual exchange benefit plans starting January 1 ...

Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad’s proprietary and clinically differentiated mental health medication test, GeneSight ...

Another key revenue source is GeneSight, a pharmacogenomic test that ... company to expand its online engagement for early gender DNA testing through the synergy provided by the acquisition ...

The insurer plans to restrict coverage for multi-gene panel pharmacogenetic tests, including Myriad's GeneSight, under its commercial and individual exchange benefit plans starting January 1, 2025.